Artivion, Inc. (NYSE:AORT) Stock Holdings Trimmed by Principal Financial Group Inc.

Principal Financial Group Inc. lessened its position in shares of Artivion, Inc. (NYSE:AORT) by 8.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 194,630 shares of the company’s stock after selling 17,094 shares during the period. Principal Financial Group Inc. owned about 0.46% of Artivion worth $5,181,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. nVerses Capital LLC acquired a new position in Artivion in the second quarter worth $28,000. RiverPark Advisors LLC bought a new position in Artivion in the second quarter worth about $55,000. RW Investment Management LLC acquired a new position in Artivion in the second quarter valued at approximately $219,000. Intech Investment Management LLC bought a new position in shares of Artivion during the second quarter valued at approximately $253,000. Finally, Tidal Investments LLC bought a new stake in shares of Artivion in the 1st quarter worth approximately $257,000. 86.37% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CAO Amy Horton sold 12,430 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total transaction of $325,417.40. Following the completion of the sale, the chief accounting officer now directly owns 139,989 shares of the company’s stock, valued at $3,664,912.02. This represents a 8.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jean F. Holloway sold 3,167 shares of Artivion stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $26.55, for a total transaction of $84,083.85. Following the completion of the transaction, the senior vice president now owns 161,932 shares in the company, valued at approximately $4,299,294.60. This trade represents a 1.92 % decrease in their position. The disclosure for this sale can be found here. 8.10% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have weighed in on AORT. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 target price on shares of Artivion in a research report on Friday, September 27th. Oppenheimer boosted their target price on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. JMP Securities initiated coverage on Artivion in a report on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 price target on the stock. Finally, Stifel Nicolaus raised their target price on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, September 13th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $31.00.

Artivion Price Performance

NYSE AORT opened at $27.16 on Thursday. The firm has a market capitalization of $1.14 billion, a PE ratio of -1,336.50 and a beta of 1.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. Artivion, Inc. has a 12 month low of $15.25 and a 12 month high of $30.00. The company’s 50 day simple moving average is $26.44 and its 200 day simple moving average is $25.52.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.